Jul 31, 2020
Lipocine Announces Derivative Suit Was Dismissed
Jul 13, 2020
Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement
May 15, 2020
Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020
May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
May 05, 2020
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial
Apr 17, 2020
U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
Mar 04, 2020
Lipocine Announces TLANDO(TM) PDUFA Date of August 28, 2020
Feb 27, 2020
Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants
Feb 24, 2020
Lipocine Announces Regulatory Path Forward for TLANDO(TM) Resubmission
Feb 11, 2020
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
Dec 06, 2019
LPCN INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Lipocine Inc.
Nov 18, 2019
SHAREHOLDER ALERT - Lipocine Inc. (LPCN) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: January 14, 2020
Nov 18, 2019
Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants
Nov 14, 2019
Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants
Nov 13, 2019
Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants
Nov 11, 2019
Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA
Oct 10, 2019
Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
Oct 01, 2019
Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019
Sep 30, 2019
First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144
Sep 23, 2019
Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America